Iksuda Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Iksuda Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10593
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Iksuda Therapeutics Ltd (Iksuda), formerly Glythera Ltd is a biotechnology company that focuses on the development of antibody drug conjugates (ADCs) and biotherapeutics for the treatment of cancer. The company develops antibody-based therapies for the treatment of cancer and broader based therapeutics. It uses its proprietary linker and stable glycan technologies permalink and premacarb to deliver solutions for development and manufacture efficacious and safe biologics to improve half-life and optimize bio-availability. The company partners with various biotech companies for its technology development activities. Iksuda is headquartered in Newcastle upon Tyne, the UK.

Iksuda Therapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Glythera Raises US$2 Million In Venture Financing 10
Partnerships 11
Avacta Enters into Agreement with Glythera 11
Licensing Agreements 12
Avacta Enters into Licensing Agreement with Glythera 12
Glythera Enters into Licensing Agreement with Cancer Research UK 13
Glythera Enters into Licensing Agreement with IONTAS 14
Iksuda Therapeutics Ltd – Key Competitors 15
Iksuda Therapeutics Ltd – Key Employees 16
Iksuda Therapeutics Ltd – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Apr 30, 2018: Glythera Names Professor Kerry Chester to Scientific Advisory Board 18
Jan 17, 2018: Glythera Appoints Chief Scientific Officer and Strengthens SAB 19
Jul 31, 2017: Glythera Appoints Dr Mike Owen as Non-executive Director 20
Jul 31, 2017: Glythera appoints new non-executive director 21
Government and Public Interest 22
Jun 06, 2017: Glythera Launches UK government funded project to develop safer and more efficacious ADCs for the treatment of difficult-to-treat tumours 22
Product News 23
Feb 21, 2017: Glythera: Demonstrates improved activity and safety of PermaLink-based ADCs 23
Other Significant Developments 24
Sep 10, 2018: Glythera announces corporate name change and rebranding to Iksuda Therapeutics 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Iksuda Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Glythera Raises US$2 Million In Venture Financing 10
Avacta Enters into Agreement with Glythera 11
Avacta Enters into Licensing Agreement with Glythera 12
Glythera Enters into Licensing Agreement with Cancer Research UK 13
Glythera Enters into Licensing Agreement with IONTAS 14
Iksuda Therapeutics Ltd, Key Competitors 15
Iksuda Therapeutics Ltd, Key Employees 16

List of Figures
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Iksuda Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Shinva Medical Instrument Co Ltd (600587):医療機器:M&Aディール及び事業提携情報
    Summary Shinva Medical Instrument Co., Ltd. (Shinva Medical) manufactures and markets medical instruments and environmental protection equipment for various healthcare markets. The company’s product portfolio includes sterilizers, radiotherapy equipment, digital diagnosis equipment, surgical instrum …
  • StarTek Inc (SRT):企業の財務・戦略的SWOT分析
    Summary StarTek Inc (StarTek) is a business process outsourcing company that offers contact center and customer engagement solutions. The company offers service solutions, technology solutions and customer experience suppor. Its service solution provides multi-channel customer interactions across vo …
  • Foundation Medicine Inc (FMI):製薬・医療:M&Aディール及び事業提携情報
    Summary Foundation Medicine Inc (Foundation Medicine), a subsidiary of F. Hoffmann-La Roche Ltd, is a molecular information products provider. The company provides molecular information and cancer research programs. It offers clinical products such as FoundationOne for solid tumors and FoundationOne …
  • Victorian WorkCover Authority:企業の戦略的SWOT分析
    Victorian WorkCover Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Global Alliance for TB Drug Development:製薬・医療:M&Aディール及び事業提携情報
    Summary Global Alliance for TB Drug Development (TB Alliance) is a non-profit organization that discovers and develops drugs to treat tuberculosis. The organization’s products include natural products, rifampin, pyrazinamide, isoniazid, macrokuds, ethambutol, and topoisomerase inhibitors. It offers …
  • SYNNEX Corp (SNX):企業の財務・戦略的SWOT分析
    SYNNEX Corp (SNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Genfit SA (GNFT)-医療機器分野:企業M&A・提携分析
    Summary Genfit SA (Genfit) is a biopharmaceutical company that develops therapeutic and diagnostic solutions for metabolic and inflammatory diseases in liver and gastroenterology diseases. The company’s product pipeline comprise GFT505, TGFTX1, TGFTX3, TGFTX4, TGFTX5 and SAN/GFT-2. Its TGFTX1 can be …
  • China Resources Enterprise Ltd:企業の戦略的SWOT分析
    China Resources Enterprise Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • FLX Bio Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary FLX Bio Inc (FLX Bio) is an immuno-oncology company that discovers and develops novel immuno-oncology agents. The company develops lead oral small molecule compound, FLX475, blocks a receptor called CCR4, found on nearly all human Treg cells that binds to secreted factors made in the tumor m …
  • Pavmed Inc (PAVM):医療機器:M&Aディール及び事業提携情報
    Summary Pavmed Inc (Pavmed) is a medical device company. The company offers disposable infusion pumps, short-term catheters, percutaneous and tissue ablation devices, and long-term vascular access devices. Its products pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; P …
  • Biotron Ltd (BIT):企業の財務・戦略的SWOT分析
    Biotron Ltd (BIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • SRS Medical Systems Inc:医療機器:M&Aディール及び事業提携情報
    Summary SRS Medical Systems Inc (SRS Medical) is a medical device company that designs, manufactures and markets diagnostics and disposable products. The company offers spanner, test systems, urodynamic systems, uroflows, uroscan bladder ultrasound systems and disposables. Its disposables products c …
  • Energy Fuels Inc (EFR):企業の財務・戦略的SWOT分析
    Energy Fuels Inc (EFR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Interstate Hotels & Resorts Inc:企業のM&A・事業提携・投資動向
    Interstate Hotels & Resorts Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Interstate Hotels & Resorts Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • National Petroleum Services Co (NAPESCO):石油・ガス:M&Aディール及び事業提携情報
    Summary National Petroleum Services Co (NAPESCO), a subsidiary of Qurain Petrochemical Industries Co, is an oil and gas service company that offers upstream and downstream services. The company's upstream oil field services includes filtration, well cementing services, downhole tools, casing hardwar …
  • Empresas Publicas De Medellin ESP-エネルギー分野:企業M&A・提携分析
    Summary Empresas Publicas De Medellin E.S.P. (EPM) is a decentralized body, operational under the ownership of Medellin municipality. It generates, transmits, and distributes electricity as well as undertakes gas distribution, wastewater and garbage treatment, and telecommunications services across …
  • PSR Group BV:製薬・医療:M&Aディール及び事業提携情報
    Summary PSR Group BV (PSR) is a contract research and staffing consultancy service provider. The company operates through two divisions such as PSR Orphan Experts and PSR Pharma Resource. Its PSR Orphan Experts is a contract research organization that concentrates on orphan drug development. The com …
  • Bank Gutmann AG:企業の戦略・SWOT・財務情報
    Bank Gutmann AG - Strategy, SWOT and Corporate Finance Report Summary Bank Gutmann AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Advanced Accelerator Applications SA (AAAP):企業の財務・戦略的SWOT分析
    Summary Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The company’s lead product candidate comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnas …
  • Daiichi Sankyo Inc-製薬・医療分野:企業M&A・提携分析
    Summary Daiichi Sankyo Inc (Daiichi Sankyo), a subsidiary of Daiichi Sankyo Company Ltd is a healthcare products provider that discovers and develops medicines for cardiovascular and metabolic disorders. The company's products comprise amlodipine, laninamivir, prasugrel, olmesartan esomeprazole, car …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆